Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Journal: The New England journal of medicine
Published: June 14, 2023
Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.
Journal: Advances in therapy
Published: April 01, 2021
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Journal: Lancet (London, England)
Published: May 06, 2020
Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.
Journal: The New England journal of medicine
Published: August 24, 2017
A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population.
Journal: Contemporary clinical trials
Published: January 08, 2016
Bayesian dose escalation in oncology with sharing of information between patient populations.
Journal: Contemporary clinical trials
Published: April 17, 2015
Showing 1-6 of 6
Last Updated: 09/26/2026